Drug intelligence / Profile preview

escitalopram + aripiprazole + omega-3 pufas

Development stage
Preclinical
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination therapy consisting of three agents: - **Escitalopram** is a selective serotonin reuptake inhibitor (SSRI) used primarily for major depressive disorder and generalized anxiety disorder. It works by inhibiting the serotonin transporter, increasing serotonin levels in the synaptic cleft[6]. - **Aripiprazole** is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. It is used for schizophrenia, bipolar disorder, and as adjunctive treatment in major depressive disorder[7]. - **Omega-3 polyunsaturated fatty acids (PUFAs)** are dietary supplements with anti-inflammatory properties; they have been studied for mood-stabilizing effects in psychiatric disorders such as depression and bipolar disorder. Their mechanism may involve modulation of cell membrane fluidity, neurotransmitter function, and reduction of oxidative stress[4][7]. This combination has been explored in research settings for mood disorders—particularly treatment-resistant depression or bipolar disorder—where augmentation strategies are needed. There is evidence supporting the use of each component individually or in pairs; however, clinical data on all three together are limited to preclinical studies or small trials[3][7]. The rationale behind this combination includes targeting multiple neurochemical pathways involved in mood regulation.

Other names
escitalopram + aripiprazole + omega-3 polyunsaturated fatty acidsescitalopram + aripiprazole + fish oil
02

Targets

HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on escitalopram + aripiprazole + omega-3 pufas.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + aripiprazole + omega-3 pufas.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call